Latest Ratios: P/E Ratio -8.5x · EV/EBITDA N/A · ROE -40.2%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4.4B | $4.4B | $4.1B | $2.1B | $951M | $1.1B | $430M | $607M | $364M | — | — |
| Enterprise Value | $4.4B | $4.3B | $3.9B | $2.1B | $922M | $894M | $341M | $572M | $319M | — | — |
| P/E Ratio → | -8.49 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 575.84 | 568.91 | 3975.39 | 514.87 | 200.82 | 1012.96 | 6051.00 | 508.42 | 149.97 | — | — |
| P/B Ratio | 3.98 | 4.41 | 3.12 | 3.83 | 3.01 | 3.29 | 2.54 | 5.18 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 562.03 | 3770.56 | 514.08 | 194.57 | 829.63 | 4796.45 | 479.29 | 131.45 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.0% | 86.0% | 100.0% | 100.0% | 100.0% | 100.0% | -80178.9% | 6.7% | -908.2% | -351.5% | -765.9% |
| Operating Margin | -6714.8% | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | -446.3% | -1026.1% |
| Net Profit Margin | -6046.2% | -6046.2% | -28720.7% | -5345.9% | -3460.4% | -9985.3% | -103960.6% | -4152.1% | -1116.8% | -447.8% | -1021.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -40.2% | -40.2% | -32.0% | -50.2% | -50.6% | -43.0% | -51.6% | -134.3% | — | — | — |
| ROA | -36.2% | -36.2% | -28.8% | -43.4% | -46.6% | -40.3% | -47.0% | -32.8% | -29.0% | -65.0% | -47.8% |
| ROIC | -37.8% | -37.8% | -30.8% | -40.6% | -59.8% | -75.4% | -69.3% | — | — | — | — |
| ROCE | -42.6% | -42.6% | -34.5% | -48.6% | -50.9% | -42.4% | -50.8% | -37.7% | -32.2% | -69.1% | -51.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.04 | 0.10 | 0.01 | 0.01 | 0.02 | 0.05 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.05 | -0.16 | -0.01 | -0.09 | -0.60 | -0.53 | -0.30 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | -1143.63 | -546.18 |
Net cash position: cash ($102M) exceeds total debt ($49M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.32 | 12.32 | 23.04 | 13.07 | 12.45 | 21.55 | 16.92 | 14.79 | 21.03 | 16.91 | 13.89 |
| Quick Ratio | 12.30 | 12.30 | 23.04 | 13.07 | 12.45 | 21.55 | 16.92 | 14.79 | 21.03 | 16.75 | 13.78 |
| Cash Ratio | 12.08 | 12.08 | 22.69 | 12.71 | 12.06 | 20.86 | 16.29 | 14.20 | 20.68 | 15.82 | 13.65 |
| Asset Turnover | — | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | 0.01 | 0.13 | 0.05 |
| Inventory Turnover | 0.53 | 0.53 | — | — | — | — | — | — | — | 65.48 | 52.04 |
| Days Sales Outstanding | — | 28.08 | 2975.51 | 850.51 | 186.85 | 687.00 | 9423.17 | 421.60 | — | 131.01 | 44.62 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $94M | $81M | $58M | $52M | $38M | $30M | $24M | $12M | $14M | $14M |
Clinical trial binary dependency
With a price-to-sales ratio of 502.81, CRNX trades at a significant premium compared to broader biotech peers, suggesting that market participants are pricing in the successful commercialization of the oral-switch thesis rather than current, non-recurring milestone-driven revenue streams reported in recent financial filings.
The extreme P/S multiple is a common artifact for pre-commercial biotechs where revenue is negligible and valuation is entirely untethered from current earnings. Investors should monitor whether this valuation can be sustained as the company approaches commercial launch, as any delay in the PATHFNDR-2 trial data could lead to a rapid compression of these multiples.
As reported in financial statements, CRNX has consistently generated negative ROIC, with the most recent quarter showing a -9.8% return, which underscores the company's current phase of heavy capital deployment into clinical development rather than efficient, value-accretive operations or sustainable capital compounding.
The persistent negative ROIC is expected for a firm in the clinical-stage biotech sector, where capital is consumed to build future intangible assets rather than current productive capacity. This trend warrants investigation into whether the platform's chemical proteomics engine can eventually generate sufficient returns to offset the massive R&D spend required to bring assets to market.
Based on the provided data, the company's cash conversion cycle is highly erratic, reaching -6815 days in 2026Q1, which reflects the lumpy nature of milestone-based revenue recognition rather than any underlying improvement in operational efficiency or management of supplier and customer payment terms.
The extreme volatility in the cash conversion cycle is a structural byproduct of a business model that lacks recurring product sales. Analysts should look past these efficiency metrics, as they are currently distorted by the timing of collaboration payments and do not reflect the actual operational leverage of the firm.
According to recent balance sheet data, the current ratio has declined from 23.04 in 2024Q4 to 18.60 in 2026Q1, indicating that while the company maintains a high liquidity position, the rapid consumption of cash to fund clinical trials is steadily eroding the firm's financial flexibility.
While the current ratio appears robust, it is misleading in the context of a high-burn biotech firm that lacks recurring cash inflows. The company's reliance on external financing to maintain this liquidity suggests that the current cash position is a temporary buffer that will likely require replenishment through dilutive equity offerings.
The price-to-sales ratio is frequently misapplied to CRNX, as it obscures the reality that current revenue is derived from non-recurring milestones rather than sustainable product demand, making it an unreliable metric for assessing the company's true long-term commercial value or its competitive positioning.
Investors should instead focus on the probability-adjusted net present value of the pipeline and the cash runway relative to the next major clinical inflection point. Relying on P/S multiples in this context may lead to an overestimation of the company's current commercial traction and an underestimation of the dilution risk inherent in its funding model.
Includes 30+ ratios · 10 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CRNX stock.
Crinetics Pharmaceuticals, Inc.'s current P/E ratio is -8.5x. This places it at the 50th percentile of its historical range.
Crinetics Pharmaceuticals, Inc.'s return on equity (ROE) is -40.2%. The historical average is -57.4%.
Based on historical data, Crinetics Pharmaceuticals, Inc. is trading at a P/E of -8.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Crinetics Pharmaceuticals, Inc. has 86.0% gross margin and -6714.8% operating margin.